Last updated: June 2, 2025
Compounded GLP-1/GIP is a dual-action injectable that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonists. It may be prescribed off-label for weight management by a licensed healthcare provider through Belle when medically appropriate.
Please review the following Important Safety Information before beginning treatment. This is not a complete list of risks or side effects. Your provider will determine if compounded GLP-1/GIP is right for you based on your individual health needs.
In rodent studies, GLP-1/GIP receptor agonists caused thyroid C-cell tumors. It is not known whether this risk occurs in humans. Compounded GLP-1/GIP is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Do not use compounded GLP-1/GIP if you:
If you are breastfeeding or plan to breastfeed, speak with your provider before starting treatment.
Speak with your provider if you have or have had:
Compounded GLP-1/GIP slows gastric emptying and may affect the absorption of certain oral medications. Your provider may modify your medication regimen accordingly.
The most frequently reported side effects of compounded GLP-1/GIP include:
These effects are generally mild and often decrease over time. If you experience persistent or severe symptoms, contact your provider.
While uncommon, compounded GLP-1/GIP may cause serious adverse effects. Contact your provider immediately if you experience:
Follow the medication label or pharmacy instructions for proper storage. Keep out of reach of children and dispose of unused or expired medication safely.
If you have questions about your treatment, side effects, or medication schedule, contact your healthcare provider directly. Do not stop or alter your treatment plan without medical supervision.